试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-14
Study of HPN424 in Patients With Advanced Prostate Cancer
编号:NCT03577028登记状态:提前终止企业 / 申办者:Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
药物 / 成分:HPN424 Fixed IV 1.3 to 150 ng/kg、HPN424 Prime Step IV 36 ng/kg Target、HPN424 1 Prime Step IV 225-300 ng/kg Target、HPN424 2 Prime Step IV 300 ng/kg Target
登记的停止原因(原文):Decision not to continue to the expansion portion of the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-14
Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin
编号:NCT04648696登记状态:提前终止企业 / 申办者:Wake Forest University Health Sciences
药物 / 成分:Vancomycin CI、Vancomycin II
登记的停止原因(原文):The study was closed due to slow enrollment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-14
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
编号:NCT04814875登记状态:提前终止企业 / 申办者:THERAPIM PTY LTD
药物 / 成分:ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
登记的停止原因(原文):For technical reasons, it was decided by the sponsor to close the ongoing ovarian cancer study, AM ATX101-03, immediately.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-14
Ketamine Pilot Study
编号:NCT05379179登记状态:提前终止企业 / 申办者:Meghan Spyres
药物 / 成分:Ketamine、Fentanyl
登记的停止原因(原文):After 20 months of active enrollment and a lack of qualified/interested subjects, the Investigator, Meghan Spyres, MD, decided to terminate recruitment before meeting the stated enrollment objectives.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
编号:NCT01345136登记状态:提前终止企业 / 申办者:Jonsson Comprehensive Cancer Center
药物 / 成分:RAD001, everolimus
登记的停止原因(原文):slow accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
编号:NCT02508324登记状态:提前终止企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:haplo-identical cells (donor)、umbilical cord blood unit (CBU)
登记的停止原因(原文):Slow accrual and change in direction of cord blood program
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain
编号:NCT02892500登记状态:提前终止企业 / 申办者:Sanford Health
药物 / 成分:bupivacaine hydrochloride and betamethasone sodium phosphate、bupivacaine hydrochloride
登记的停止原因(原文):Inability to enroll subjects
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer
编号:NCT02995330登记状态:提前终止企业 / 申办者:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
药物 / 成分:Bone marrow transplantation、Cytoxan、testosterone cypionate
登记的停止原因(原文):lack of accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
编号:NCT03275402登记状态:提前终止企业 / 申办者:Y-mAbs Therapeutics
药物 / 成分:131I-omburtamab
登记的停止原因(原文):Corporate business decision. Not due to safety or efficacy concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-02-13
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
编号:NCT04337931登记状态:提前终止企业 / 申办者:Apexigen America, Inc.
药物 / 成分:sotigalimab
登记的停止原因(原文):Business decision (not due to safety reason).
查看官方原始记录 ↗